@misc{oai:repo.qst.go.jp:00066847,
 author = {Yoshii, Yukie and Yoshimoto, Mitsuyoshi and Matsumoto, Hiroki and Tashima, Hideaki and Iwao, Yuma and Takuwa, Hiroyuki and Yoshida, Eiji and Wakizaka, Hidekatsu and Yamaya, Taiga and Zhang, Ming-Rong and Sugyo, Aya and Hanadate, Sayaka and Tsuji, Atsushi and Higashi, Tatsuya and 吉井 幸恵 and 吉本 光喜 and 松本 博樹 and 田島 英朗 and 岩男 悠真 and 田桑 弘之 and 吉田 英治 and 脇坂 秀克 and 山谷 泰賀 and 張 明栄 and 須尭 綾 and 花舘 明香 and 辻 厚至 and 東 達也},
 month = {Jun},
 note = {Objectives: Peritoneal dissemination is a frequent cause of death in colon cancer and it is particularly hard to improve the survival of patients with late-phase peritoneal dissemination. We have reported that intraperitoneal radioimmunotherapy (ipRIT) using a theranostic agent 64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab was effective to treat peritoneal dissemination of small lesions. We have also reported that PET-guided surgery with this agent using OpenPET system, which has open space for conducting surgery while monitoring objects at high resolution in real-time PET, was useful to detect and resect intraperitoneal large tumor masses of unknown position. Based on these findings, we examined efficacy of combination use of ipRIT and PET-guided surgery with 64Cu-labeled cetuximab, to treat late-phase peritoneal dissemination of colon cancer, in a mouse model. Methods: Human colon cancer HCT116 cells stably expressing red fluorescent protein (HCT116-RFP) were intraperitoneally injected into a mouse. Four weeks later, mice with late-phase peritoneal dissemination were randomized into 4 groups (n = 8/group). For combination treatment with ipRIT and OpenPET-guided surgery, a therapeutic dose of 64Cu-labeled-cetuximab (22.2 MBq) was ip injected into mice for ipRIT, and OpenPET-guided surgery was performed at 48 h after administration. For comparison purposes, the ipRIT + sham operation, OpenPET-guided surgery-only, or sham operation-only (control) groups were also prepared. For the ipRIT + sham operation group, 64Cu-labeled-cetuximab (22.2 MBq) was injected in a similar manner and the sham operation consisting of resecting only the tumors observed with the naked eye was conducted without OpenPET observation. For the OpenPET-guided surgery-only group, mice were ip administered an imaging dose of 64Cu-labeled-cetuximab (7.4 MBq), and OpenPET-guided surgery was performed at 24 h after the administration. Results: Combination of ipRIT and OpenPET-guided surgery inhibited tumor growth and extended survival significantly compared to the sham operation-only control (P < 0.05). OpenPET-guided surgery alone and ipRIT with a sham operation slightly extended survival, but the differences were not significant compared to the sham operation-only control. Conclusions: We demonstrated the efficacy of a combination therapy of ipRIT and PET-guided surgery for late-phase peritoneal dissemination of colon cancer using a mouse model. Our data suggested that this method could provide a novel strategy to treat late-phase peritoneal dissemination from colon cancer., SNMMI 2018 Annual Meeting},
 title = {Efficacy of combination use of intraperitoneal radioimmunotherapy and PET-guided surgery with 64Cu-labeled-cetuximab in a mice model of colon cancer peritoneal dissemination},
 year = {2018}
}